Just a moment, the page is loading...
The Supported Studies Programme

For the latest updates on GSK’s response to COVID-19, please click here.

Global Health


Within Global Health we specifically focus on diseases that predominantly affect low- and lower middle-income countries, with projects targeting infectious diseases such as malaria, tuberculosis, enteric diseases and neglected tropical diseases.

[For Tafenoquine - Last updated January 2024]
In Malaria our key areas of interest are

   •   Tafenoquine for radical cure of P. vivax malaria
   •   G6PD diagnostic and treatment with Tafenoquine in patients with P. vivax malaria.
   •   Use of Tafenoquine with Chloroquine
   •   Tafenoquine effectiveness in patients with P.vivax malaria.
   •   PK/PD study in patients with P.vivax malaria.
   •   Comparative study of Tafenoquine vs Primaquine.
   •   Healthcare resource use and direct cost to the healthcare system including
         o   the economic impact of labour force participation and absenteeism due to Vivax
         o   the economic impact of cure.

GSK are more likely to support studies aligned to our current areas of interest when they are innovative and contribute to scientific knowledge relating to a product, a medical condition or advancing a technology. GSK Global Health encourages submissions throughout the year.

© 2001-2024 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.